---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004266"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T01:00:34.837231+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology CMO Valerie Jansen departs; severance includes 9-month salary and equity vesting

## Summary
- CMO Valerie Jansen stepped down effective March 31, 2025.
- Separation agreement provides lump-sum payment equal to 9 months of salary.
- COBRA premium reimbursement for up to 9 months post-separation.
- Accelerated vesting of equity awards for shares that would have vested over 9 months.
- No successor CMO named; company has not disclosed a replacement.

## SEC filing metadata
- accession: 0001558370-25-004266
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000155837025004266/0001558370-25-004266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000155837025004266/elev-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004266
- JSON: https://secwatch.observer/filing/0001558370-25-004266.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004266.txt

## Key facts
- Executive change
  Valerie M. Jansen departed as Chief Medical Officer at Elevation Oncology, Inc..
  - Action: stepped down
  - Role: Chief Medical Officer
  source text: agreed that Dr. Jansen would step down as Chief Medical Officer effective March 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837025004266/0001558370-25-004266-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.